Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Animesh Pardanani, M.D.

Back to Research Profile

  1. Hussein K, Pardanani AD, van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2009 Nov 09. [Epub ahead of print]
    View PubMed
  2. Patnaik MM, Caramazza D, Gangat N, Hanson CA, Pardanani A, Tefferi A. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2009 Nov 06. [Epub ahead of print]
    View PubMed
  3. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009 Oct 29; 114(18):3769-72. Epub 2009 Aug 27.
    View PubMed
  4. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA, Tefferi A. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2009 Oct 22. [Epub ahead of print]
    View PubMed
  5. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2009 Oct 22. [Epub ahead of print]
    View PubMed
  6. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009 Oct 09. [Epub ahead of print]
    View PubMed
  7. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009 Sep; 33(9):1199-203. Epub 2009 Feb 27.
    View PubMed
  8. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009 Aug; 23(8):1441-5. Epub 2009 Mar 19.
    View PubMed
  9. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009 Jun 4; 113(23):5727-36. Epub 2009 Apr 10.
    View PubMed
  10. Fink SR, Belongie KJ, Paternoster SF, Smoley SA, Pardanani AD, Tefferi A, Van Dyke DL, Ketterling RP. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res 2009 Jun; 33(6):843-6. Epub 2008 Dec 31.
    View PubMed
  11. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009 May; 23(5):900-4. Epub 2009 Mar 05.
    View PubMed
  12. Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009 May; 23(5):905-11. Epub 2009 Mar 05.
    View PubMed
  13. Tefferi A, Sirhan S, Sun Y, Lasho T, Finke CM, Weisberger J, Bale S, Compton J, LeDuc CA, Pardanani A, Thorland EC, Shevchenko Y, Grodman M, Chung WK. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res 2009 May; 33(5):662-4. Epub 2008 Oct 19.
    View PubMed
  14. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009 May; 84(5):265-7.
    View PubMed
  15. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009 Apr; 82(4):255-9. Epub 2008 Feb 10.
    View PubMed
  16. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008 Jul; 22(7):1299-307. Epub 2008 May 22.
    View PubMed
  17. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008 Jun 15; 14(12):3906-15.
    View PubMed
  18. Huang J, Li CY, Mesa RA, Wu W, Hanson CA, Pardanani A, Tefferi A. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008 Jun 15; 112(12):2726-32.
    View PubMed
  19. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A. Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis. Am J Hematol 2008 Jun; 83(6):451-3.
    View PubMed
  20. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008 May; 83(5):363-5.
    View PubMed
  21. Tefferi A, Gangat N, Wolanskyj AP, Schwager S, Pardanani A, Lasho TL, Mesa R, McClure RF, Li CY, Hanson CA. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis. Eur J Haematol 2008 May; 80(5):386-90. Epub 2008 Jan 23.
    View PubMed
  22. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008 Apr; 83(4):457-9.
    View PubMed
  23. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008 Apr; 22(4):756-61. Epub 2008 Jan 24.
    View PubMed
  24. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 2008 Mar 1; 111(5):2785-9. Epub 2007 Nov 15.
    View PubMed
  25. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, Li CY, Ketterling RP, Tefferi A. Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 2008 Mar; 80(3):197-200. Epub 2007 Dec 07.
    View PubMed
  26. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008 Jan; 22(1):23-30. Epub 2007 Sep 20.
    View PubMed
  27. Lim KH, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol 2008; 119(4):194-8. Epub 2008 Jun 20.
    View PubMed
  28. Pardanani A, Verstovsek S. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. Cancer J 2007 Nov-Dec; 13(6):384-91.
    View PubMed
  29. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N, Pardanani A, Hanson CA, Ketterling RP. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007 Sep; 21(9):2074-5. Epub 2007-05-03.
    View PubMed
  30. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007 Sep; 21(9):1960-3. Epub 2007 Jun 28.
    View PubMed
  31. Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007 Sep; 21(9):1964-70. Epub 2007 Jun 21.
    View PubMed
  32. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007 Sep; 7(9):673-83.
    View PubMed
  33. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, Gilliland DG, Tefferi A. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007 Sep; 25(9):2358-62. Epub 2007 May 31.
    View PubMed
  34. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007 Aug; 21(8):1827-8. Epub 2007 Apr 26.
    View PubMed
  35. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007 Aug; 138(3):354-8.
    View PubMed
  36. Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007 Aug; 21(8):1658-68. Epub 2007 May 31.
    View PubMed
  37. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007 Jun 1; 109(11):2279-84.
    View PubMed
  38. Tefferi A, Huang J, Schwager S, Li CY, Wu W, Pardanani A, Mesa RA. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007 May 15; 109(10):2083-8.
    View PubMed
  39. Tefferi A, Pardanani A. Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc 2007 May; 82(5):599-604.
    View PubMed
  40. Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007 May; 31(5):691-4.
    View PubMed
  41. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med 2007 May; 131(5):784-91.
    View PubMed
  42. Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gilliland DG, Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006 Dec; 135(5):683-7.
    View PubMed
  43. Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica 2006 Dec; 91(12 Suppl):ECR57.
    View PubMed
  44. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006 Nov 15; 108(10):3472-6. Epub 2006 Jul 25.
    View PubMed
  45. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006 Aug; 30(8):965-70. Epub 2006 Jan 06.
    View PubMed
  46. Tefferi A, Pardanani A. Mutation screening for JAK2V617F: when to order the test and how to interpret the results. Leuk Res 2006 Jun; 30(6):739-44. Epub 2006 Feb 07.
    View PubMed
  47. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006 Jun; 133(5):468-92.
    View PubMed
  48. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc 2006 Apr; 81(4):553-63.
    View PubMed
  49. Pardanani A, Akin C, Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19(3):595-615.
    View PubMed
  50. Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005; 114(1):41-51.
    View PubMed
  51. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004 Nov 15; 104(10):3038-45.
    View PubMed
  52. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004 Oct 1; 104(7):1931-9.
    View PubMed
  53. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients. Leuk Res 2004 Aug; 28(8):777-83.
    View PubMed
  54. Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol 2004 Jun; 79(5):441-7.
    View PubMed
  55. Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Current Hematology Reports 2004 May; 3(3):197-202.
    View PubMed
  56. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004 May; 28(Suppl 1):S47-S52.
    View PubMed
  57. Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004 Feb; 28(2):127-31.
    View PubMed
  58. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004 Jan; 11(1):58-64.
    View PubMed
  59. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004; 89(7):871-3.
    View PubMed
  60. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NCP, Cools J, Gilliland DG, Dewald GW, Tefferi A. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003 Nov 1; 102(9):3093-6.
    View PubMed
  61. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003 Oct; 27(10):883-5.
    View PubMed
  62. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NCP, Tefferi A. Imatinib for systemic mast-cell disease. Lancet 2003 Aug 16; 362(9383):535-7.
    View PubMed
  63. Pardanani A, Reeder TL, Kimlinger TK, Baek JY, Li CY, Butterfield JH, Tefferi A. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 2003 Aug; 27(8):739-42.
    View PubMed
  64. Pardanani AD, Morice WG, Hoyer JD, Tefferi A. Chronic basophilic leukemia: a distinct clinico-pathologic entity? Eur J Haematol 2003 Jul; 71(1):18-22.
    View PubMed
  65. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NCP, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003 May 1; 101(9):3391-7.
    View PubMed
  66. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder GE, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003 Apr 1; 101(7):2534-41.
    View PubMed
  67. Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis. Mayo Clin Proc 2003 Mar; 78(3):301-6.
    View PubMed
  68. Pardanani A, Witzig TE, Schroeder G, McElroy EA, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Kyle RA, Greipp PR, Gertz MA, Rajkumar SV. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003 Feb 1; 101(3):827-30.
    View PubMed
  69. Pardanani A, Kimlinger TK, Reeder TL, Li CY, Tefferi A. Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder. Br J Haematol 2003 Feb; 120(4):691-4.
    View PubMed
  70. Pardanani A, Baek JY, Li CY, Butterfield JH, Tefferi A. Systemic mast cell disease without associated hematologic disorder: A combined retrospective and prospective study. Mayo Clin Proc 2002 Nov; 77(11):1169-75.
    View PubMed
  71. Pardanani A, Wieben ED, Spelsberg TC, Tefferi A. Primer on medical genomics Part IV: Expression proteomics. Mayo Clin Proc 2002 Nov; 77(11):1185-96.
    View PubMed
  72. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002 May 15; 99(10):3854-6.
    View PubMed
  73. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002 May 4; 359(9317):1577-8.
    View PubMed
  74. Baek JY, Li CY, Pardanani A, Butterfield JH, Tefferi A. Bone marrow angiogenesis in systemic mast cell disease. J Hematother Stem Cell Res 2002 Feb; 11(1):139-46.
    View PubMed
  75. Baek JY, Tefferi A, Pardanani A, Li CY. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res 2002 Jan; 26(1):83-90.
    View PubMed
  76. Pardanani A, Gambacurta A, Ascoli F, Royer WE Jr. Mutational destabilization of the critical interface water cluster in Scapharca dimeric hemoglobin: Structural basis for altered allosteric activity. J Mol Biol 1998; 284:729-9.
    View PubMed
  77. Pardanani A, Gibson QH, Colotti G Royer WE Jr. Mutation of residue Phe 97 to Leu disrupts the central pathway of cooperativity in Scapharca dimeric hemoglobin. J Biol Chem 1997 May 16; 272(20):13171-9.
    View PubMed
  78. Royer WE Jr, Pardanani A, Gibson QH, Peterson ES, Friedman JM. Ordered water molecules as key allosteric mediators in a cooperative dimeric hemoglobin. Proc Natl Acad Sci U S A 1996 Dec 10; 93(25):14526-31.
    View PubMed
  79. Summerford CM, Pardanani A, Betts AH, Poteete AR, Colotti G, Royer WE Jr. Bacterial expression of Scapharca dimeric hemoglobin: a simple model system for investigating protein cooperatively. Protein Eng 1995 Jun; 8(6):593-9.
    View PubMed
  80. Salomon M, Adams S, Pardanani A, Vazquez S, Humphreys RE, Lew RA. Comparison of actual and random-positioning-model distributions of peptide scavenging and T cell-presented sites in antigenic proteins. Vaccine 1993; 11(10):1067-73.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.